Stock Market Trends, Covid-19 Treatments, Burford Results, Lookers Accounting and Medica

The stock market seems to be returning to normal with a positive trend over the last month despite the economy being in a complete shambles as a result of the “lock-down”. The Government is incurring massive costs to bail-out companies, support the NHS and pay workers to do nothing. We have yet to see the real economic impact of those measures on the Government’s finances. But investors seem to be euphoric because they now realise we are not all going to die from the Covid-19 epidemic and there are signs we will be able to get back to work soon.

There are also indications that vaccines to prevent the disease, or treatments for it, may be available in the next few months. One of the best commentators on the epidemic because of his scientific background is Matt Ridley who I met many years ago in circumstances he probably prefers to forget. He publishes a blog which is here: http://www.rationaloptimist.com/blog/ plus he has several good books published which I can recommend. His latest blog article is entitled “The contenders – and challenges – in the race to cure Covid” and is a good review of the field.

One interesting suggestion is the possible use of monoclonal antibodies to replicate antibodies from those infected with the disease and use them to treat other people. This might be very expensive from my knowledge of other such treatments but if the treatment is effective it might only require an injection every few months. It might be affordable for developed countries.

The diversion of NHS resources to treat Covid-19 patients is creating many problems though. Minor operations and non-urgent consultations are being cancelled. You can see the impact of this in the results reported by Medica Group (MGP) earlier this month. The company provides teleradiology services to the NHS and others. This is what it said: “In terms of Routine activity, the Company is experiencing a decline of around 90% in activity with many NHS hospitals having already suspended non-urgent elective procedures”. Reduced A&E admissions are also having an impact. But the company remains positive and can reduce its cost base substantially. ShareSoc has organised a webinar with this company this evening which may be interesting as I do not hold it.

Another company I do not hold is Burford Capital (BUR) which announced results this morning. This company has been in the news a lot because of a shorting attack. This is what the Chairman had to say: “2019 was a year of contrasts, marked by the continued expansion of our business yet also by the disruption of a meritless short attack. Though our business fundamentals remained strong, investor confidence was dented, causing shareholders to urge changes to our governance”. The announcement contains many positive comments about the progress on litigation, the future prospects, and balance sheet strength.

The accounts are not easy to understand and the Annual Report consists of 163 pages so I have not read it all. No doubt other people will comment on it in detail. But one simple thing I did do was look at the income and cash flow statements.

This is a company where the profits do not turn into cash. Comprehensive income was down from $342 million to $194 million but after changes in “capital provisions” the net cash outflow was $8.3 million. There are also doubts as to whether the legal awards which are recognised in the accounts can actually be collected. The share price is up over 25% today at the time of writing.

Another company worth mentioning as I like to cover cases of defective accounts is that of motor dealer Lookers Group (LOOK) – I have never held it. A few days ago the company gave a “Trading and Operational Update”. It included coverage of the fraud investigation which is now expected to result in a non-cash charge of £4 million in the 2019 financial accounts. Those have now been delayed until June. The investigation has also been extended across all divisions and more charges are expected.

The share price of Lookers was 185p in early 2016. It’s now about 21p. Such events totally undermine investor confidence in the accounts of public companies and suggest much tougher action is required to ensure accounts reported by companies are accurate and not subject to fraud or misrepresentation. Auditors surely are one group who need to take a lead on this as frequently when frauds are identified they have been running for several years.

As I said in my book Business Perspective Investing, “financial accounts don’t matter because they cannot be relied upon”. That’s certainly the case at present and it’s better to look at other measures of the quality of a business. That is particularly the case at present when the Covid-19 epidemic is distorting the results of companies and making it very difficult to forecast future financial numbers.

Better to look at other factors such as your trust in the management, the market position of the company and its future prospects.

Roger Lawson (Twitter: https://twitter.com/RogerWLawson )

Post Date: April 28, 2020

Mark Bentley says:

29th April 2020 at 10:30 am

It appears that AstraZeneca (AZN) is very active in the search for Covid-19 therapies. In today’s Q1 announcement (amongst other significant contributions to the UK fight against Covid-19), it says:

“The Company has mobilised research efforts to find new ways to help target the virus, reduce the cytokine storm, arising from an overactive immune response, and potentially protect organs. As part of the effort to target the virus, the Company is identifying novel SARS-CoV-2-neutralising monoclonal antibodies that can be used for treatment, as well as a prophylaxis against viral infection.

AstraZeneca is evaluating the use of Calquence, approved in a number of countries for the treatment of chronic lymphocytic leukaemia, in the Phase II CALAVI trial, which is assessing the suppression of the cytokine storm that inflames the lungs and other organs of some COVID-19 patients. The Company is also looking at protecting organs in the Phase III DARE-19 trial, assessing whether Farxiga, an oral medicine that has demonstrated benefits in heart failure and kidney disease, can potentially reduce organ failure. The Company has also joined the UK Government’s ACCORD-2 proof-of-concept clinical-trial platform, to speed the development of medicines for patients with COVID-19.”

See https://www.investegate.co.uk/astrazeneca-plc–azn-/rns/azn–first-quarter-2020-results/202004290700042394L/

rogerwlawson says:

29th April 2020 at 10:51 am

Fascinating – if the problem in some people is an excessive immune response, perhaps a drug that suppresses the immune system might help, of which there are several. I should be OK in that case. But why are the elderly more impacted because they have weaker immune systems?

Alan Selwood says:

29th April 2020 at 2:10 pm

That’s a very useful link to Matt Ridley’s article.

As for whether the suppression of the immune response and the greater susceptibility of the elderly is connected, I can’t say, but I think that we may be talking about 2 different things:
a) that the virus causes the immune system to go into overdrive (as might be the case with lupus, rheumatoid arthritis, pneumonia and similar), and perhaps also that the elderly are not as good as preventing this over-reaction, and
b) that elderly people have lost a lot of the ability they had in earlier years to generate a quick and high-volume response to a virus attack by quickly identifying the virus’s RNA pattern as alien and harmful and neutralising it.

All supposition on my part, because I am not medically trained!

Group description:	Our group is interested in sustainable investing and our goal is to identify and evaluate businesses that will thrive through innovation and their transition to a ‘One Planet Economy’. By leveraging the skills of group members, we aim to deeply understand these businesses, particularly focusing on how they develop long-term valuable benefits for their customers. Each year, we plan to evaluate around seven businesses to identify opportunities where our valuation exceeds the market price. A successful outcome is defined as achieving a compound annual growth rate (CAGR), including dividends, of 10% over a decade.
Meeting Type/Venue:	Meetings are in-person in a pub near to Waterloo station in London.
Meeting Frequency/Timing:	Meetings are bi-monthly on a Monday from 10:45am to 4:30pm. Members are expected to also pay for their own lunch which secures the group free use of a private room in the pub. The cost is expected to be £35-40 per person, per meeting, in addition to your SIGnet membership fee.

Group description:	SIGnet Taunton is a new group with around 10 keen members at present, with a range of investment styles and experience. We welcome new members.
Meeting Type/Venue:	In person meetings at a golf club near to the centre of Taunton.
Meeting Frequency/Timing:	We meet on the first Monday of every month at a golf club near to the centre of Taunton, 11am until 3pm with a lunch break.

Group description:	An online group for those who are new to investing, or have only been investing for a few years. Including topics such as: – What is a share or a bond, why and how to buy them. – Comparing funds, unit trusts, Investment trusts and exchange traded funds. – Portfolio management and diversification. – ISAs, pensions, SIPPS and how to save tax. – How terms such as PE ratio and dividend yield are used to value a share. – How to use technical analysis or charting.
Meeting Type/Venue:	Online using Zoom.
Meeting Frequency/Timing:	Meetings are usually held on the last Monday of the month at 7:00pm.

Group description:	An online group for those who already have some experience in investing. Covering topics such as finding companies to invest in, financial statements and ratios, valuation / margin of safety, analysis of companies and investment trusts and exchange traded funds.
Meeting Type/Venue:	Online using Zoom.
Meeting Frequency/Timing:	Meetings are usually held on the last Wednesday of the month at 7:00pm.

Group description:	The Equity Income Group welcomes investors of all levels of experience, from beginners to advanced. The focus of meetings is on dividend paying Investment Trusts, though there is also discussion around individual shares.
Meeting Type/Venue:	Meetings are held online.
Meeting Frequency/Timing:	Meetings are held every 6 weeks on a weekday between 7 and 8:30pm.

Stock Market Trends, Covid-19 Treatments, Burford Results, Lookers Accounting and Medica

3 Comments

Leave a Comment Click here to cancel reply.

Group description:	A welcoming group open to all types of investors. Typical meeting content is to have a deep dive presentation on a topic selected by the participants and a session on buy/ sell/ key lessons learnt last month.
Meeting Type/Venue:	In person at a friendly pub close to Piccadilly Circus
Meeting Frequency/Timing:	Monthly during the evening on the first Wednesday of the month.

Group description:	All levels of experience welcome. A typical meeting agenda includes: – Macro Environment – Trades: Members review existing positions and identify securities with promising TA entry patterns or setups and with suitable risk/reward. Any security, long, short, futures, options may be considered. The convener takes actual positions in trades and maintains his own detailed ledger, accurately measuring performance of individual securities and cumulative activity. Members are notified by e-mail prior to the entries or exits that are decided upon. Following each meeting an updated copy of the ledger is circulated together with the next meeting agenda. Members may wish to maintain similar ledgers of their own but there is no obligation to do so. – Technical Analysis: Techniques and systems used in trades. Members can request discussion of particular aspects of TA.
Meeting Type/Venue:	Online via Zoom
Meeting Frequency/Timing:	The first Tuesday of every month from 7 to 9pm

Group description:	Group focused on active investing, primarily in small / medium cap UK equities.
Meeting Type/Venue:	Regular Zoom meetings interspersed with occasional face to face meetings and social activities in the North West.
Meeting Frequency/Timing:	Monthly on Saturdays at 10am.

Group description:	Our group covers a wide spectrum of mainly stock market investing and trading from equities – which include shares, ETF’s Investment and Unit Trusts. We normally rotate the meeting chairperson (responsible for creating, with member’s help, suitable agendas) and a meeting presenter (members take it in turns to provide a 15 to 45 minute presentation on a subject of their choice). Various investing topics of interest are regularly discussed such as software, brokers, investing categories and markets and any related topics of interest.
Meeting Type/Venue:	Meetings will be returning to in-person in a private room at a West London golf club, close to an underground station. In the meantime monthly video calls and an in-between meeting email group will continue.
Meeting Frequency/Timing:	In-person meetings will be held on the second Wednesday of each month in the afternoons, following a golf club one course lunch.